Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome

BackgroundCritically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodie...

Full description

Bibliographic Details
Main Authors: Maria Orietta Borghi, Asmaa Beltagy, Emirena Garrafa, Daniele Curreli, Germana Cecchini, Caterina Bodio, Claudia Grossi, Simonetta Blengino, Angela Tincani, Franco Franceschini, Laura Andreoli, Maria Grazia Lazzaroni, Silvia Piantoni, Stefania Masneri, Francesca Crisafulli, Duilio Brugnoni, Maria Lorenza Muiesan, Massimo Salvetti, Gianfranco Parati, Erminio Torresani, Michael Mahler, Francesca Heilbron, Francesca Pregnolato, Martino Pengo, Francesco Tedesco, Nicola Pozzi, Pier Luigi Meroni
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
anti-phospholipid antibodies
β2-glycoprotein I
prothrombin
autoimmunity
COVID-19
thrombosis
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.584241/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.584241/full

Similar Items